STL Index for: corticosteroids

Real-World Insights from Atopic Dermatitis Patients Treated with Abrocitinib

This real-world case series intends to illustrate a variety of moderate-to-severe AD patient cases to help guide discussions around abrocitinib and describe its treatment strategies used by experts in the field.

Dupilumab for the Treatment of Prurigo Nodularis

Dupilumab: A groundbreaking FDA and Health Canada-approved treatment for Prurigo Nodularis (PN). This innovative therapy targets IL-4 and IL-13 signalling, effectively reducing inflammation, pruritus, and lesions. Its approval marks a paradigm shift in PN management, offering new hope for patients.

A Practical Guide to Advanced Topical Drug Delivery Systems in Dermatology

This guide will help you navigate the benefits of recent advancements in topical drug formulations and delivery systems. These innovations address limitations seen in older formulations, ensuring efficient and uniform delivery of active ingredients to target areas, improving patient acceptability, and enhancing treatment outcomes.

Managing Psoriasis with Topical Agents – Where Do We Stand?

Psoriasis vulgaris is a chronic, immune-mediated inflammatory skin disease affecting 2-4% of the Canadian population. While most psoriasis vulgaris cases are mild-to-moderate (>80%) and do not require systemic treatment, these cases can still be particularly challenging to treat as topical therapies present limitations, including efficacy and administration, leading to poor long-term treatment compliance and unsatisfactory treatment responses. The intent of this paper is to provide physicians with a clinically relevant review of the currently available and newly developed topical therapies...

Chlormethine Gel for the Treatment of Mycosis Fungoides (Cutaneous T-cell Lymphoma) in Canada

Chlormethine gel, a topical antineoplastic agent, has shown safety and efficacy in phase II trials and real-world data for treating adult Mycosis Fungoides patients. Despite potential skin-related side effects, chlormethine gel offers a convenient, skin-directed treatment for stage IA and IB MF-CTCL, addressing an unmet need in Canada.

Tralokinumab for Moderate-to-Severe Atopic Dermatitis in Adults

Tralokinumab is an effective and safe treatment for adult patients with moderate-to-severe AD. It may be used alone or in combination with TCS. This biologic can be considered first-line treatment after failure of or intolerance to topical therapies.

Casmo Algorithm for Management of Hormonal Therapy-Related Cutaneous Adverse Effects in Oncology Patients

Breast and prostate cancer patients frequently use hormonal therapy to improve treatment outcomes and survival. However, these medications can be associated with numerous dermatologic adverse effects.

Toxic Epidermal Necrolysis: A Review of Past and Present Therapeutic Approaches

Toxic epidermal necrolysis (TEN) is an immune-mediated, severe cutaneous adverse drug reaction characterized by epidermal detachment affecting greater than 30% body surface area.

CaSMO Management of Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: A Practical Primer

The management of cirAEs starts with physician awareness and patient education on the occurrence of toxicities, preventive measures, and skincare using gentle cleansers, moisturizers, and sunscreen started before immunotherapy begins and ongoing thereafter as part of the lifestyle.

Halobetasol Propionate 0.01% Lotion for Plaque Psoriasis and Corticosteroid-Responsive Dermatoses

A novel topical corticosteroid, halobetasol propionate (HP) 0.01% lotion (Bryhali™), has recently been introduced for the treatment of plaque psoriasis and corticosteroid-responsive dermatoses in adults.

Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications

Currently, JAK inhibitors are only FDA approved for dermatologic, rheumatologic, and hematologic conditions. Recent studies show the utility of JAK inhibitors in treating atopic dermatitis, psoriasis, psoriatic arthritis, vitiligo, and alopecia areata.

Canadian Skin Management in Oncology Group (Casmo) Algorithm for the Prevention and Management of Acute Radiation Dermatitis

The Canadian Skin Management in Oncology Group (CaSMO) developed an algorithm for the reduction of severity and management of acute RD, which follows previous publications from this group that addressed general oncology-treatment related cutaneous adverse events [AEs], prevention, and skin management.

Optimal Use of Crisaborole in Atopic Dermatitis – An Expert Guidance Document

Mild to moderate atopic dermatitis (AD) is often controlled by behavioral measures such as skincare and avoidance of triggers in addition to topical treatments such as topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and crisaborole, a phosphodiesterase-4 inhibitor (PDE4-I).

Crisaborole 2% Ointment for Mild-to-Moderate Atopic Dermatitis

Crisaborole provides a novel and safe treatment option for mild-to-moderate AD.

Use of Topical Crisaborole for Treating Dermatitis in a Variety of Dermatology Settings

The discussed cases reflect the panels’ real-world clinical experience with crisaborole for the treatment of patients with AD and the off-label treatment of irritant dermatitis.

Diagnosis and Management of Atopic Dermatitis for Family Physicians: A Clinical Review

Atopic dermatitis (AD) is a chronic and pruritic inflammatory disease that affects a wide age range of patients causing significant impact on their quality of life. There has been a recently updated consensus paper on the treatment of mild-to-moderate AD published by an expert panel of dermatologists and pediatricians. Family physicians are well equipped to manage...

Update on the Management of Vitiligo

Vitiligo is a psychosocially debilitating disease requiring a multidisciplinary approach to treatment. Patients should be made aware of all of the options available geared at repigmentation and depigmentation prior to formulating a treatment plan.

Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis

Crisaborole represents a novel and efficacious therapeutic approach for the treatment of mild to moderate Atopic Dermatitis and demonstrates early and continued decrease in pruritus, which improves quality of life and reduces the potential risk of infection and scarring.

Atopic Dermatitis: A Practical Guide to Management

A group of dermatologists with extensive experience in managing pediatric and adult patients with atopic dermatitis developed practical recommendations for the management of atopic dermatitis based on expert consensus opinion and the best available medical evidence.

Management of Adult Moderate-to-Severe Atopic Dermatitis: A Practical Guide for Primary Care

Atopic dermatitis (AD) is a chronic, relapsing, pruritic, inflammatory condition involving the skin which can have a significant impact on the quality of life. This article will guide the family practitioner on how to manage adults with moderate-to-severe AD and when to refer for specialist management.

A Dermatologist’s Guide to Infection Screening Prior to Initiating Immunosuppressive Therapy

In this review, we summarize the most common immunosuppressant medications currently used in dermatology, and provide recommendations for infection screening prior to initiating treatment.

Rituximab: Uses in Dermatology

Rituximab is an anti-CD20 monoclonal antibody with considerable potential in dermatology due to an increase in off-label indications. Off-label use of rituximab, indications, side-effects, and dosing are some of the topics discussed.

Dupilumab, A Monoclonal Antibody for Atopic Dermatitis: A Review of Current Literature

Standard therapies for atopic dermatitis have fallen short, prompting efforts to discover novel therapeutics for this disease. Dupilumab, a fully human monoclonal antibody that inhibits the actions of both IL-4 and IL-13, has shown promise.

Off-Label Uses of Topical Calcineurin Inhibitors

Topical calcineurin inhibitors (TCIs) have been proposed as an alternative, long-term treatment option to topical corticosteroids. Currently, TCIs are only approved for treatment of atopic dermatitis in patients 2 years of age or older. This article reviews the off-label uses of TCIs and their efficacy in the treatment of cutaneous diseases.

Current Management of Scalp Psoriasis

The scalp is involved in up to 80% of individuals with psoriasis. Topical treatment with corticosteroids with or without vitamin D3 analogues is the mainstay of treatment, but other therapies such as light treatment and systemic drugs including biologics are discussed.

Pregnancy-Specific Skin Disorders

This articles discusses pregnancy-specific skin disorders: Pemphigoid gestationis, polymorphic eruption of pregnancy, atopic eruption of pregnancy, and intrahepatic cholestasis of pregnancy. Clinical presentation, potential for fetal complications, pathogenesis, diagnosis, and treatment are discussed.

Updates on the Management of Autoimmune Blistering Diseases

Autoimmune blistering diseases are rare, but potentially debilitating characterized by varying degrees of mucosal and cutaneous bullae formation. This article discusses individually tailored treatment, diagnosis, severity, comorbidities, and tolerance for systemic therapy.

Metastatic Melanoma: Optimizing Outcomes by Managing Dermatologic Toxicities Associated with Novel Therapies

The last couple of years have seen the beginning of a new era in the treatment of metastatic melanoma. This article focuses on BRAF inhibitors and immune modulators which have demonstrated an overall survival benefit, and the importance of limiting adverse events.

Steroid-Sparing Properties of Emollients in Dermatology

This article reviews topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) to manage inflammatory conditions, its risks with long-term use, and the role of moisturizing as important therapeutic adjuncts.

Therapeutic Options for Vitiligo

Vitiligo is a disease that presents with depigmented skin and is associated with significant psychosocial effects. Disease progression can be unpredictable and management is challenging. This article discusses etiology, management, and treatment options.

Treatment of Infantile Hemangiomas with Beta-Blockers: A Review

Infantile hemangiomas are the most common tumors occurring in early childhood, with a prevalence of approximately 5-10% of infants. Discussions centres around β-blockers, which appear to be highly effective in treating IH are at the centre of discussion.

Methotrexate: Role of Treatment in Skin Disease

Methotrexate has been used for over half a century to treat a wide spectrum of skin conditions. This article delves into research on the pharmacogenetic properties of the drug as well as the variety of skin conditions that Methotrexate is used to treat.

Urticaria and Angioedema: A Rational Approach to Diagnosis and Therapy

Urticaria and angioedema and some forms of this disorder may be increasing in both prevalence and severity due to changes in medications, environment and other factors. This review focuses on a rational approach to differential diagnosis and therapy of the most common forms of urticaria and angioedema.

Laser Management of Acne Scarring

Acne scarring is often challenging to manage. This article discusses various laser treatments that are helpful in addressing abnormal color and texture in order to improve the appearance of an acne scar as well as review the appropriate use and side-effects of these treatments.

A New Paradigm Shift in the Management of Atopic Dermatitis (Pediatric Edition)

This article reviews atopic dermatitis, and its shift in the philosophy behind treatment and management. Preventative therapy, long-term strategy, and focus on quality of life.

Atopic Dermatitis: The Skin Barrier and the Role of Ceramides (Pediatric Edition)

This article discusses atopic dermatitis, its pathogenesis, and general treatment principles as well as specific therapeutic options.

Pediatric Psoriasis

Several variants of psoriasis are seen in children, the most prevalent types include plaque, guttate, and psoriatic diaper rash; pustular and erythrodermic psoriasis are less frequently observed. This article discusses genetic susceptibility, and environmental triggers are discussed.

A Practical Approach to Classification and Treatment of Scars

This paper focuses on a comprehensive and practical approach to classifying and managing scars in terms of colour and texture, and discusses topical treatments accessible to family physicians in more detail.

A New Paradigm Shift in the Management of Atopic Dermatitis

Atopic eczema (or atopic dermatitis) is a common inflammatory skin condition that dermatologists, pediatricians, family physicians, and primary-care providers see on a daily basis. Treatments, mechanism of action, preventative therapies, and the skin barrier are discussed.

Topical Management of Recalcitrant Psoriasis and Eczema

Psoriasis and eczema, especially atopic eczema, are two of the most common cutaneous conditions seen by family physicians and dermatologists. This article discusses the etiology of psoriasis and eczema, immunologic abnormalities, and the role of immune mediators.

POPULAR

Advertisement